DiaMedica Therapeutics (DMAC) Assets Average (2019 - 2026)

DiaMedica Therapeutics (DMAC) has reported Assets Average for 8 consecutive years, with $49.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average rose 39.52% year-over-year to $49.0 million; the trailing twelve-month figure through Jun 2026 stood at $49.0 million (up 39.52% YoY), and the FY2025 full-year result was $53.9 million, up 7.17% from the prior year.
• Assets Average retreated to $49.0 million in Q2 2026 per DMAC's latest filing, from $57.2 million in the prior quarter.
• Across five years, Assets Average topped out at $60.1 million in Q3 2023 and bottomed at $32.3 million in Q1 2023.
• Historically, Assets Average has averaged $47.2 million across 5 years, with a median of $47.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Assets Average surged 76.61% in 2022, then plunged 33.71% in 2025.
• Over 5 years, Assets Average stood at $35.7 million in 2022, then jumped by 57.2% to $56.1 million in 2023, then slipped by 11.96% to $49.4 million in 2024, then advanced by 19.77% to $59.2 million in 2025, then dropped by 17.17% to $49.0 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $49.0 million, $57.2 million, and $59.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.